Results 11 to 20 of about 10,318 (317)

GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes. [PDF]

Hepatol Commun
Choi J, Mitchell G, Nguyen VH, Przybyszewski E, Song J, Carroll A, Michta M, Almazan E, Simon TG, Chung RT.   +9 more
europepmc   +2 more sources

Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety [PDF]

Cardiovascular Diabetology
Background Glucagon like peptide-1 receptor agonist (GLP-1RA) use in individuals with high atherosclerotic cardiovascular disease (ASCVD) risk reduces major adverse cardiovascular events (MACE). However, its clinical impact, in terms of numbers needed to
Ansel Shao Pin Tang, Jovan Teng Yuan Hsu, Sheena Kar Shuan Chong, Jingxuan Quek, Genevieve Shek, Farisah Sulaimi, Kai En Chan, Vickram Vijay Anand, Bryan Chong, Anurag Mehta, Sue-Anne Toh, Mark Muthiah, Georgios K. Dimitriadis, Carel W. le Roux, Mark Yan-Yee Chan, Mamas Andreas Mamas, Yip Han Chin, Nicholas W. S. Chew   +17 more
doaj   +6 more sources

Addressing Confounders in GLP‐1RA Effects on ALD Outcomes [PDF]

Liver International
Chi‐Kuei Hsu, Chia‐Chih Kuo, Chih‐Cheng Lai   +2 more
openalex   +3 more sources

ABSTRACT NUMBER: ESOC2026A262 STROKE RISK WITH SGLT2I, GLP-1RA, AND DPP-4I IN TYPE 2 DIABETES: REAL-WORLD LONGITUDINAL ESTIMATES IN THE CONTEXT OF TRIAL AND OBSERVATIONAL EVIDENCE [PDF]

Eur Stroke J
Anastasios Mavridis, Tamar Abzhandadze, Dongni Buvarp, Björn Eliasson, Mia von Euler, Adam Viktorisson, Katharina STIBRANT SUNNERHAGEN   +6 more
europepmc   +2 more sources

Temporally Phenotyping GLP-1RA Case Reports with Large Language Models: A Textual Time Series Corpus and Risk Modeling

medRxiv
Sayantan Kumar, Jeremy C. Weiss
europepmc   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population [PDF]

Advances in Therapy, 2017
Hiep Nguyen
exaly   +2 more sources

<i>Alea Iacta Est</i>: Casting the Die in Favor of Evidence-Based, Rational GLP-1RA Use. [PDF]

Hosp Pharm
Belančić A.
europepmc   +3 more sources

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United StatesPlain-Language Summary

Kidney Medicine, 2023
Rationale & Objective: Information regarding disparities in initiating sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in patients with chronic kidney disease (CKD) is limited.
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
doaj   +1 more source

GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching [PDF]

Liver International
Jonggi Choi, Vy H Nguyen, Tracey G Simon   +2 more
exaly   +2 more sources

The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study [PDF]

Diabetes & Metabolism Journal, 2023
We compared the glycemic efficacy of treatment intensification between quadruple oral antidiabetic drug therapy and once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA)-based triple therapy in patients with poorly controlled type 2 diabetes ...
Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek   +7 more
doaj   +1 more source